Schizophrenia
Conditions
Keywords
schizophrenia, reboxetine, cognitive, behavior
Brief summary
30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.
Detailed description
all participants will be administered panss, sans, esrs, calgary, progesterom, sexual functioning scale, ham-a, covy, hamilton depression scale, and cgi and cgi improved rating on the first visit, as well as blood tests, ecg and weight. they will then be tested using a computer cognitive test (cogscan test) that lasts about 45 minutes. next, they will be given either a two week dose of placebo or treatment (2 mg \* 2 daily for first week, then 4 mg. day, 2 mg. night for the second week). after two weeks they the dose is increased to 4 mg. \* 2 daily. at four weeks all tests are readministered, as well as at six weeks. the study is concluded at 6 weeks, following a readministration of tests. physical examination is also administered at the conclusion.
Interventions
DRUGreboxetine adjuvant therapy
Sponsors
Abarbanel Mental Health Center
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* schizophrenia all types * 18\>
Exclusion criteria
* uti * \>65 * non organic state * no depression treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sans, panss, hamilton, ham-a, calgary, physical examination, cogscan test | — |
Secondary
| Measure | Time frame |
|---|---|
| esrs, progesterom, sexual functioning, covy, cgi, cgi improved | — |
Countries
Israel
Contacts
Primary Contactstanislav baranchik, md
Outcome results
None listed